Indivior ended internal development of an opioid use disorder candidate after a phase 2 trial missed its primary endpoint.
- Home |
- Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
- April 30, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
